Seven Eight Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Seven Eight Capital’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,398	Closed	-$80.8K	–	620
2023 Q3	$80.8K	Sell	10,398 -5,585	-35%	-$54.6K	0.01%	576
2023 Q2	$155K	Buy	+15,983	New	+$166K	0.03%	464
2022 Q4	–	Sell	-17,881	Closed	-$134K	–	410
2022 Q3	$134K	Sell	17,881 -17,527	-50%	-$152K	0.03%	452
2022 Q2	$356K	Sell	35,408 -77,895	-69%	-$871K	0.14%	224
2022 Q1	$1.4M	Buy	+113,303	New	+$1.75M	0.19%	168
2021 Q4	–	Sell	-288,840	Closed	-$6.39M	–	458
2021 Q3	$6.39M	Buy	288,840 +243,760	+541%	+$3.87M	0.62%	23
2021 Q2	$584K	Buy	+45,080	New	+$574K	0.08%	394
2020 Q4	–	Sell	-36,434	Closed	-$537K	–	408
2020 Q3	$537K	Buy	+36,434	New	+$528K	0.12%	326
2020 Q2	–	Sell	-24,300	Closed	-$353K	–	329
2020 Q1	$353K	Buy	+24,300	New	+$429K	0.09%	280

Other funds holding AUPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Seven Eight Capital's AUPH Position: Q4 2023 in Review

Seven Eight Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 10,398 shares — an estimated $80.8K sold.

Seven Eight Capital first reported a position in AUPH in Q1 2020 and held it in 9 quarters. The position peaked at $6.39M in Q3 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

Seven Eight Capital reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Seven Eight Capital sold 10,398 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $80.8K.
Seven Eight Capital first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 9 quarters.
Seven Eight Capital's Aurinia Pharmaceuticals position peaked at $6.39M in Q3 2021.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.